Tokyo Tape
Sign in
← Alfresa Holdings

Quarterly report · Q2

2784.TEDINET S100PL0M
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥1.33T2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥2.59T2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥1.29T2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥10.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.1bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥11.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥32.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥11.0bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥11.1bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥10.3bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥32.2bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥7.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥7.0bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥1.33Tat 2022-09-30Cons.Assets
Total assets¥1.30Tat 2022-03-31Cons.Assets
Total assets¥1.33Tat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥852.3bnat 2022-09-30Cons.Liabilities
Total liabilities¥832.2bnat 2022-03-31Cons.Liabilities
Net assets / equity¥481.9bnat 2022-09-30Cons.Net assets
Net assets / equity¥471.8bnat 2022-03-31Cons.Net assets
Net assets / equity¥492.0bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥169.5bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥180.4bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥168.2bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥179.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥176.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥169.1bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥10.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥36.5bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥20.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥15.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow¥2.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥29.2bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.9bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥34.62022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥24.12022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥153.572021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥33.022021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥17.72021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio36.1%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio36.2%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio36.9%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥15.2bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥245m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.18T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.17T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥8.3bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥23.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥6.6bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥842m
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥17.9bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥14m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥124.1bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥123.8bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥305m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥1.35T
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥1.33T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥10.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥14.2bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30¥182m
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥1.13T
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥7.9bn
jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥7.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥22.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.9bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥16.8bn
jpcrp040300-q2r_E02962-000Medical Related Businessreportable segmentsegment profit2021-04-01 → 2021-09-30−¥285m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥129.9bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥129.6bn
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥284m
jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥1.30T
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥1.29T
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥14.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 539
ItemContextValueUnit
Raw materials and suppliesCurrentQuarterInstant6062000000JPY
Other caPrior1YearInstant88908000000JPY
Other caCurrentQuarterInstant89763000000JPY
Allowance for doubtful accounts caPrior1YearInstant-2252000000JPY
Allowance for doubtful accounts caCurrentQuarterInstant-1661000000JPY
Current assetsPrior1YearInstant1016471000000JPY
Current assetsCurrentQuarterInstant1024567000000JPY
Buildings and structures netPrior1YearInstant63708000000JPY
Buildings and structures netCurrentQuarterInstant62540000000JPY
LandPrior1YearInstant70018000000JPY
LandCurrentQuarterInstant71318000000JPY
Other net ppePrior1YearInstant29031000000JPY
Other net ppeCurrentQuarterInstant37952000000JPY
Property plant and equipmentPrior1YearInstant162758000000JPY
Property plant and equipmentCurrentQuarterInstant171812000000JPY
GoodwillPrior1YearInstant2913000000JPY
GoodwillCurrentQuarterInstant2792000000JPY
Other iaPrior1YearInstant15894000000JPY
Other iaCurrentQuarterInstant15428000000JPY
Intangible assetsPrior1YearInstant18807000000JPY
Intangible assetsCurrentQuarterInstant18220000000JPY
Investment securitiesPrior1YearInstant87284000000JPY
Investment securitiesCurrentQuarterInstant100157000000JPY
Other ioaPrior1YearInstant22444000000JPY
Other ioaCurrentQuarterInstant24693000000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-3774000000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-5237000000JPY
Investments and other assetsPrior1YearInstant105954000000JPY
Investments and other assetsCurrentQuarterInstant119613000000JPY
Noncurrent assetsPrior1YearInstant287520000000JPY
Noncurrent assetsCurrentQuarterInstant309646000000JPY
AssetsPrior1YearInstant1303991000000JPY
AssetsCurrentQuarterInstant1334214000000JPY
Notes and accounts payable tradePrior1YearInstant755250000000JPY
Notes and accounts payable tradeCurrentQuarterInstant782492000000JPY
Short term loans payablePrior1YearInstant48000000JPY
Short term loans payableCurrentQuarterInstant20000000JPY
Income taxes payablePrior1YearInstant10922000000JPY
Income taxes payableCurrentQuarterInstant8673000000JPY
Provision for bonusesPrior1YearInstant6835000000JPY
Provision for bonusesCurrentQuarterInstant6275000000JPY
Provision for directors bonusesPrior1YearInstant407000000JPY
Provision for directors bonusesCurrentQuarterInstant195000000JPY
Provision for share based remuneration clPrior1YearInstant44000000JPY
Provision for share based remuneration clCurrentQuarterInstant－JPY
Provision for share based remuneration for directors and other officers clPrior1YearInstant59000000JPY
Provision for share based remuneration for directors and other officers clCurrentQuarterInstant－JPY
Other clPrior1YearInstant29245000000JPY
Other clCurrentQuarterInstant25708000000JPY
Current liabilitiesPrior1YearInstant802813000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass